Iyiad Alabdul Razzak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Iyiad Alabdul Razzak has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Hirsh D. Trivedi
Department of Internal Medicine, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA
2 shared publications - Darren Evanchuk
Division of Hematology and Oncology, St. Elizabeth's Medical Center, Boston University School of Medicine, Boston, MA
1 shared publication - Manish Tandon
Division of Gastroenterology, St. Elizabeth's Medical Center, Boston University School of Medicine, Boston, MA
1 shared publication - Maram Alenzi
Gastroenterology Department, Beth Israel Deaconess Center Harvard Medical School Boston Massachusetts USA
1 shared publication - Mazen Noureddin
Houston Research Institute, Houston, Texas, USA
1 shared publication - Michael P. Curry
Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
1 shared publication
Latest Publications
- Open Access
- 1 June 2024
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 11 (6) , e01373
Gastric Non-Hodgkin Lymphoma in a Helicobacter pylori-Infected Patient
Resent a rare case of PG-DLBCL diagnosed with H. pylori. An 82-year-old man presented to clinic with complaints of worsening epigastric pain. He underwent an endoscopy which revealed 1 large nonbleeding gastric ulcer. Histopathological and immunohistochemical analysis confirmed PG-DLBCL. He was started on H. pylori eradication (HPE) and subsequently completed 6 cycles of R-mini-CHOP chemotherapy. Since then, the patient maintained clinical and radiological remission for more than a year without recurrence. PG-DLBCL is an aggressive Non-hodgkin lymphoma (NHL) that usually presents late. It has been shown that HPE without chemotherapy in DLBCL codiagnosed with H. pylori is not an effective strategy. Thus, the standard of care for patients would be HPE and chemotherapy as in our patient. More research is needed to better understand association between H. pylori and DLBCL....
- 1 June 2024
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 11 (6) , e01373
Open AccessGastric Non-Hodgkin Lymphoma in a Helicobacter pylori-Infected Patient
Resent a rare case of PG-DLBCL diagnosed with H. pylori. An 82-year-old man presented to clinic with complaints of worsening epigastric pain. He underwent an endoscopy which revealed 1 large nonbleeding gastric ulcer. Histopathological and immunohistochemical analysis confirmed PG-DLBCL. He was started on H. pylori eradication (HPE) and subsequently completed 6 cycles of R-mini-CHOP chemotherapy. Since then, the patient maintained clinical and radiological remission for more than a year without recurrence. PG-DLBCL is an aggressive Non-hodgkin lymphoma (NHL) that usually presents late. It has been shown that HPE without chemotherapy in DLBCL codiagnosed with H. pylori is not an effective strategy. Thus, the standard of care for patients would be HPE and chemotherapy as in our patient. More research is needed to better understand association between H. pylori and DLBCL....
- Open Access
- 2 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (3) , 880
From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) affecting a quarter of the global population
- 2 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (3) , 880
Open AccessFrom Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) affecting a quarter of the global population
- Open Access
- 27 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (23) , 7340
Post-Transplant Hepatic Steatosis: A Condition Not to Overlook
Recurrent or de novo steatotic liver disease (SLD) following liver transplantation (LT) is a rising concern among liver transplant recipients
- 27 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (23) , 7340
Open AccessPost-Transplant Hepatic Steatosis: A Condition Not to Overlook
Recurrent or de novo steatotic liver disease (SLD) following liver transplantation (LT) is a rising concern among liver transplant recipients